Lead Product(s) : Amcenestrant,Letrozole
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi Provides Update on Amcenestrant Clinical Development Program
Details : Amcenestrant (SAR439859) is an orally bioavailable SERD that demonstrates pure ER antagonism in vivo. Compared with other SERD agents, amcenestrant provides optimal ER antagonism and degradation.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2022
Lead Product(s) : Amcenestrant,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet its primary endpoint of improving progression-free survival, in patients with breast cancer.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal study (AMEERA-3) of amcenestrant versus physician’s choice in locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer is fully recruited; readout expected in H2 2021.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2021
Lead Product(s) : Amcenestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi to Showcase Data from Its Transformative Oncology Pipeline at 2021 ASCO Meeting
Details : Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2021
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi's Emerging Oncology Pipeline Highlighted at the AACR Virtual Annual Meeting II
Details : Preclinical data for Sanofi's investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research (AACR) Virtual Annual Meeting II on June 22-24.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi to Showcase Oncology Portfolio and Innovative Pipeline at ASCO20 Virtual Scientific Program
Details : Company going to present clinical data on its oncology portfolio including data on its Phase 1/2 study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/HER2- metastatic breast cancer.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Amcenestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi To Present Oncology Strategy, Provide Update On Portfolio And Emerging Pipeline
Details : The four areas of strategic focus within oncology, including multiple myeloma, skin, lung, and breast cancers. Sanofi’s four anchor oncology treatments include Sarclisa® (isatuximab-irfc) and Libtayo® (cemiplimab-nwlc), and the pipeline programs.
Product Name : SAR439859
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
